Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours

G. H. Hall, L. W. Turnbull, I. Richmond, L. Helboe, Stephen Atkin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1, 2, 3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1, 2, 3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P < 0.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular SSt5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalBritish Journal of Cancer
Volume87
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Somatostatin Receptors
Somatostatin
Blood Vessels
Neoplasms
G-Protein-Coupled Receptors
Ovarian Neoplasms
Immunohistochemistry
Therapeutics

Keywords

  • Angiogenesis
  • Immunohistochemistry
  • Ovarian cancer
  • Somatostatin
  • Somatostatin receptors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. / Hall, G. H.; Turnbull, L. W.; Richmond, I.; Helboe, L.; Atkin, Stephen.

In: British Journal of Cancer, Vol. 87, No. 1, 2002, p. 86-90.

Research output: Contribution to journalArticle

Hall, G. H. ; Turnbull, L. W. ; Richmond, I. ; Helboe, L. ; Atkin, Stephen. / Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. In: British Journal of Cancer. 2002 ; Vol. 87, No. 1. pp. 86-90.
@article{56569ecc468d41f8bfdf98d7b9764ea2,
title = "Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours",
abstract = "Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1, 2, 3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90{\%}) of malignant and 26/35 (74{\%}) benign tumours expressed somatostatin. Receptors sst1, 2, 3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P < 0.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular SSt5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.",
keywords = "Angiogenesis, Immunohistochemistry, Ovarian cancer, Somatostatin, Somatostatin receptors",
author = "Hall, {G. H.} and Turnbull, {L. W.} and I. Richmond and L. Helboe and Stephen Atkin",
year = "2002",
doi = "10.1038/sj.bjc.6600284",
language = "English",
volume = "87",
pages = "86--90",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours

AU - Hall, G. H.

AU - Turnbull, L. W.

AU - Richmond, I.

AU - Helboe, L.

AU - Atkin, Stephen

PY - 2002

Y1 - 2002

N2 - Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1, 2, 3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1, 2, 3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P < 0.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular SSt5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.

AB - Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native somatostatin expression and its receptors sst1, 2, 3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours expressed somatostatin. Receptors sst1, 2, 3 and 5 were expressed variably in epithelial, vascular and stromal compartments for both benign and malignant tumours. Somatostatin was found to correlate significantly with stromal sst1 (P=0.008), epithelial sst1 (P < 0.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular SSt5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic potential.

KW - Angiogenesis

KW - Immunohistochemistry

KW - Ovarian cancer

KW - Somatostatin

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=0036649145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036649145&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600284

DO - 10.1038/sj.bjc.6600284

M3 - Article

VL - 87

SP - 86

EP - 90

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -